Hala Alshayeb is a Nephrology physician. OpenAlex indexes 13 publications with 318 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
613 23rd St Ste 510
Ashland, KY 411012878
Telephone
606-329-9335Provider last certified this registry record 24 Jan 2024.
Clinical trials
- Vitamin D Metabolism in Chronic Kidney Disease Patients
Sponsor: Memphis VA Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Calliditas Therapeutics US Inc.Program year20257 payments
- Bayer Healthcare Pharmaceuticals Inc.Program year20257 payments
- Lilly USA, LLCProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
79.4%Beta blocker16.8%Labetalol Hcl41%Carvedilol38%Metoprolol Tartrate22%Part D<11 patientsLoop diuretic15.6%Furosemide83%Bumetanide17%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
7%SGLT2 inhibitor4.3%Farxiga100%Part D<11 patientsProvitamin D2 Compound2.7%Vitamin D2100%Part D<11 patientsGenitourinary & hormones
5%alpha-Adrenergic Blocker5%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Activation of FGF-23 Mediated Vitamin D Degradative Pathways by Cholecalciferol
The Journal of Clinical Endocrinology & Metabolism
2014 - Treatment Of Chronic Kidney Disease Mineral Bone Disorder (CKD‐MBD)
Primer on the metabolic bone diseases and disorders of mineral metabolism
2013 - Post transplant bone disease
Journal of Nephrology & Therapeutics
2013 - CKD–Mineral and Bone Disorder Management in Kidney Transplant Recipients
American Journal of Kidney Diseases
2012
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”